APA (7th ed.) Citation

El Zarif, T., Pond, G., Nassar, A., Adib, E., Freeman, D., Thomas, J., . . . Sonpavde, G. (2022). 116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis. Annals of Oncology, 33, S591. https://doi.org/10.1016/j.annonc.2022.07.148

Chicago Style (17th ed.) Citation

El Zarif, T., et al. "116P Any Regression of Tumor (ART) as an Intermediate Endpoint in Patients (pts) Treated with Immune Checkpoint Inhibitors (ICI): A Pan-cancer Analysis." Annals of Oncology 33 (2022): S591. https://doi.org/10.1016/j.annonc.2022.07.148.

MLA (9th ed.) Citation

El Zarif, T., et al. "116P Any Regression of Tumor (ART) as an Intermediate Endpoint in Patients (pts) Treated with Immune Checkpoint Inhibitors (ICI): A Pan-cancer Analysis." Annals of Oncology, vol. 33, 2022, p. S591, https://doi.org/10.1016/j.annonc.2022.07.148.